Where do we stand? Functional imaging in acute and chronic pulmonary embolism with state-of-the-art CT

被引:10
|
作者
Meyer, Mathias [1 ,3 ]
Haubenreisser, Holger [1 ,3 ]
Sudarski, Sonja [1 ,3 ]
Doesch, Christina [2 ,3 ]
Ong, Melissa M. [1 ]
Borggrefe, Martin [2 ,3 ]
Schoenberg, Stefan O. [1 ]
Henzler, Thomas [1 ,3 ]
机构
[1] Heidelberg Univ, Med Fac Mannheim, Univ Med Ctr Mannheim, Inst Clin Radiol & Nucl Med, D-68167 Mannheim, Germany
[2] Heidelberg Univ, Med Fac Mannheim, Univ Med Ctr Mannheim, Dept Med 1, D-68167 Mannheim, Germany
[3] DZHK German Ctr Cardiovasc Res Partner Site Mannh, Mannheim, Germany
关键词
Pulmonary embolism; Chronic pulmonary embolism; Computed tomography; Dual-energy; Pulmonary perfusion; Right heart failure; DUAL-ENERGY CT; RIGHT-VENTRICULAR DYSFUNCTION; MULTIDETECTOR COMPUTED-TOMOGRAPHY; PERFUSION DEFECT SCORE; BLOOD-VOLUME IMAGES; SEVERITY ASSESSMENT; ANGIOGRAPHY; LUNG; HYPERTENSION; DIAGNOSIS;
D O I
10.1016/j.ejrad.2015.09.015
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Nowadays, CT pulmonary angiography (CTPA) is the diagnostic imaging modality of choice for acute and chronic pulmonary embolism (PE) in order to assess vascular anatomy and parenchymal morphology. Over the past decade, several prognostic CTPA markers associated with an increased risk of adverse clinical events and in-hospital mortality have been evaluated, namely cardiac chamber dimensions, obstruction scores, and visualization of iodinated contrast material in the lung parenchyma by dual-energy (DE) CTPA. This article reviews the current status and potential prognostic advantages of CTPA or DE CTPA with its recent developments for accessing right ventricular dysfunction and the assessment of first pass lung perfusion with DE CTPA in the diagnosis of acute and chronic PE. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:2432 / 2437
页数:6
相关论文
共 50 条
  • [41] High-Risk Acute Pulmonary Embolism Where Do We Go From Here?
    Tehrani, Behnam N.
    Batchelor, Wayne B.
    Spinosa, David
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (01) : 44 - 46
  • [42] Flavopiridol: where do we stand in chronic lymphocytic leukemia?
    T S Lin
    P Porcu
    Leukemia, 2004, 18 : 243 - 246
  • [43] Cannabinoids in anesthesia and chronic pain: Where do we stand?
    Pandey, Khushboo
    Hoda, Wasimul
    SAUDI JOURNAL OF ANAESTHESIA, 2024, 18 (01) : 100 - 104
  • [44] Flavopiridol: where do we stand in chronic lymphocytic leukemia?
    Lin, TS
    Porcu, P
    LEUKEMIA, 2004, 18 (02) : 243 - 246
  • [45] Topical Pramoxine in Chronic Pruritus: Where do We Stand?
    Agarwal, Akash
    Das, Anupam
    Hassanandani, Trashita
    Podder, Indrashis
    Panda, Maitreyee
    INDIAN JOURNAL OF DERMATOLOGY, 2021, 66 (05) : 576 - +
  • [46] Acute coronary syndromes in Europe - where do we stand?
    Sousa, P.
    Mimoso, J.
    Marques, N.
    Santos, W.
    Pereira, S.
    Brandao, V.
    Jesus, I.
    EUROPEAN HEART JOURNAL, 2012, 33 : 634 - 634
  • [47] Where do we stand with radioimmunotherapy for acute myeloid leukemia?
    Walter, Roland B.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2022, 22 (05) : 555 - 561
  • [48] State implementation of TANF: where do we stand in 2001?
    Lurie, I
    EVALUATION AND PROGRAM PLANNING, 2001, 24 (04) : 379 - 388
  • [49] State-of-the-art imaging of pulmonary embolic disease
    Davey, NC
    Davey, IC
    McDermott, VG
    Smith, TP
    Patz, EF
    Erasmus, JJ
    RADIOLOGY, 1996, 201 : 373 - 373
  • [50] State-of-the-Art CT Imaging of the Left Atrium
    Karády J.
    Whitaker J.
    Rajani R.
    Maurovich-Horvat P.
    Current Radiology Reports, 4 (8)